A failed acquisition bid, U.S. pricing deals, and boardroom drama pose challenges for the Danish pharma giant.
Get this delivered to your inbox, and more info about our products and services.
Renault, Elekta, Tietoevry and a number of others have recently reset expectations with investors.
Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate…
Eli Lilly's stock is soaring while Novo Nordisk is sinking. Why it makes sense to stick with the market winner, despite its…
TD Cowen still sees shares of Novo Nordisk adding 6% from here.
Novo Nordisk is losing market share despite its having a "comprehensive portfolio" compared to peers, the firm said.
Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026…
